180 related articles for article (PubMed ID: 2354446)
1. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Gomer CJ; Ferrario A
Cancer Res; 1990 Jul; 50(13):3985-90. PubMed ID: 2354446
[TBL] [Abstract][Full Text] [Related]
2. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Ferrario A; Kessel D; Gomer CJ
Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
[TBL] [Abstract][Full Text] [Related]
5. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
7. The effects of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro.
Sheyhedin I; Aizawa K; Araake M; Kumasaka H; Okunaka T; Kato H
Photochem Photobiol; 1998 Jul; 68(1):110-4. PubMed ID: 9679456
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
10. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
11. High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6.
Ohtani K; Usuda J; Ichinose S; Ishizumi T; Hirata T; Inoue T; Maehara S; Imai K; Kubota M; Tsunoda Y; Yamada M; Tsutsui H; Yamada K; Kuroiwa Y; Furukawa K; Okunaka T; Kato H
Int J Oncol; 2008 Feb; 32(2):397-403. PubMed ID: 18202762
[TBL] [Abstract][Full Text] [Related]
12. In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy.
Nelson JS; Roberts WG; Berns MW
Cancer Res; 1987 Sep; 47(17):4681-5. PubMed ID: 2957047
[TBL] [Abstract][Full Text] [Related]
13. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response.
McMahon KS; Wieman TJ; Moore PH; Fingar VH
Cancer Res; 1994 Oct; 54(20):5374-9. PubMed ID: 7923168
[TBL] [Abstract][Full Text] [Related]
14. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
Webber J; Leeson B; Fromm D; Kessel D
J Photochem Photobiol B; 2005 Feb; 78(2):135-40. PubMed ID: 15664500
[TBL] [Abstract][Full Text] [Related]
15. Detection of photodynamic therapy-induced early apoptosis in human salivary gland tumor cells in vitro and in a mouse tumor model.
Kaneko T; Chiba H; Yasuda T; Kusama K
Oral Oncol; 2004 Sep; 40(8):787-92. PubMed ID: 15288832
[TBL] [Abstract][Full Text] [Related]
16. Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma.
Peng Q; Moan J; Ma LW; Nesland JM
Cancer Res; 1995 Jun; 55(12):2620-6. PubMed ID: 7780978
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins.
Gomer CJ; Ryter SW; Ferrario A; Rucker N; Wong S; Fisher AM
Cancer Res; 1996 May; 56(10):2355-60. PubMed ID: 8625311
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of delta-aminolevulinic acid-induced protoporphyrin as a photosensitizer for photodynamic therapy in vivo.
Hua Z; Gibson SL; Foster TH; Hilf R
Cancer Res; 1995 Apr; 55(8):1723-31. PubMed ID: 7712481
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): implication of topical NPe6-photodynamic therapy.
Wong TW; Aizawa K; Sheyhedin I; Wushur C; Kato H
J Pharmacol Sci; 2003 Oct; 93(2):136-42. PubMed ID: 14578580
[TBL] [Abstract][Full Text] [Related]
20. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398.
Harvey EH; Webber J; Kessel D; Fromm D
Am J Surg; 2005 Mar; 189(3):302-5. PubMed ID: 15792755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
